Are your patients ready for a different treatment choice for their relapsing multiple sclerosis?
For RMS patients like yours, disease activity can mean disability progression1
More frequent relapses, MRI activity, and new or worsening symptoms are all signs of active RMS.1,2
8 out of 10 patients with RMS
reported that their relapse lasted
one week or more.3*
Only 1 in 4 patients with RMS are
started on high efficacy therapies
Nearly 1 in 2 patients with early-stage
RMS starting platform therapy or
dimethyl fumarate experience
treatment failure in the first
year of treatment.5,6‡
*Results from the MS in America Study, an online survey conducted in 2013 and completed by 2562 adult MS patients who were US residents or citizens living abroad.3
†Analysis of US Symphony Anonymous Patient Level Data from November 2019-October 2020 pertaining to patients with MS. High efficacy therapies include ocrelizumab, natalizumab, alemtuzumab, fingolimod, siponimod, cladribine, and ozanimod.4
‡A retrospective analysis of outcomes in newly diagnosed adult patients (N=1661) with ≥1 DMT claims of interferon, glatiramer acetate, or dimethyl fumarate from January 2016-March 2018 who were identified using a large US administrative claims database.5,6
Meet a few of the more than 8,000 patients prescribed
KESIMPTA as a
first-line treatment, or after experience with
Mom, real estate agent, RMS patient; initiated Kesimpta in 2020*
I started experiencing relapses on my previous treatment,
and my doctor wanted me to try KESIMPTA.
Kristin was ready for a different choice to manage her disease activity.
Despite being treated with a DMT, Kristin continued to be affected by RMS.
Experienced recent relapse despite being on an oral first-line treatment
Evidence of lesion activity in recent MRI
Continued relapses despite treatment
Wants to find a treatment that works for her
Wants to reduce relapses in her life
Partner, stepmom, medical dosimetrist, RMS patient; initiated KESIMPTA in 2020*
My doctor had found 2 new lesions. Now I take KESIMPTA which helps me manage my RMS.
Rachel loves to travel. She doesn't love dealing with RMS.
After trying 2 DMTs, Rachel was looking for more control over disease activity.
Previously on Aubagio®
2 new lesions on recent MRI
2 separate neurologists recommended KESIMPTA
Worried about potential side effects
Wants less frequent dosing
Husband, dad, aeronautical engineer, RMS patient; initiated
KESIMPTA in 2021*
I chose KESIMPTA over infusions for my first RMS treatment.
I can administer it myself at home.
Being diagnosed with RMS was overwhelming.
Walt wanted a treatment that could help manage his RMS activity.
An MRI for severe headache led to recent RMS diagnosis
No previous DMT
Dislikes needles, refused infusions
Wants to treat at home
Feels at ease with Sensoready Pen, despite initial concern about injections
B-cell treatments have become an important tool in treating RMS8†
Annual NBRx share of B-cell therapies
B-cell therapies now account for more than
40% of all new prescriptions in RMS
†Based on annual NBRx Share Data from 2018 through November 2021. B-cell therapies include KESIMPTA (7%) and Ocrevus® (ocrelizumab) (35%). KESIMPTA was approved in August 2020.
Have you considered B-cell therapies for your
Start patients on KESIMPTA todayDOWNLOAD START FORM
Submit a Start Form by fax or online at CoverMyMeds®VISIT COVERMYMEDS®
DMT=disease-modifying therapy; MOA=mechanism of action; MRI=magnetic resonance imaging; MS=multiple sclerosis; RMS=relapsing MS.
*Actual KESIMPTA patient who was compensated for their time. Individual results may vary.
References: 1. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl1)S5-S48. 2. Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636. doi:10.1212/NXI.0000000000000636 3. MS in America: relapse frequency and duration. Accessed February 22, 2022. https://multiplesclerosis.net/living-with-ms/multiple-sclerosis-relapses 4. Data on file. US Symphony ALPD Q4 2020 Data. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2020. 5. Conway D, Hersh C, Wang M, Yang F, Deshpande C. Treatment failure in patients with multiple sclerosis initiating frequently used first line therapies. PO02. Poster presented at: 8th Joint ACTRIMS-ECTRIMS Meeting MS; September 11-13, 2020; Virtual. 6. Data on file. HEOR US unmet needs. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2020. 7. Data on file. Q4 2021 results. Novartis Pharmaceuticals Corp; 2021. 8. Data on file. Ocrevus Px demographics and Rx behavior. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2021.